Biospecimen Repository Core

生物样本存储库核心

基本信息

批准号：
9979809
负责人：
Hikmat Al-Ahmadie
金额：
$ 20.18万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-24 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9979809
关键词：
Animals Antibodies Archives BCG Live Bacillus Calmette-Guerin Therapy Bioinformatics Biological Biological Assay Biological Markers Biological Specimen Banks Biometry Blood Blood specimen Cell Separation Cisplatin Clinical Clinical Chemistry Clinical Laboratory Improvement Amendments Clinical Research Communities Consent Consultations DNA DNA Damage DNA analysis Data Diagnostic Disease Disease Management Doctor of Philosophy Documentation Enrollment Ensure Evaluation Excision Formalin Freezing Fresh Tissue Gene Expression Profiling Genes Genetic Genomics Goals Guidelines Heterogeneity Human Image Immunohistochemistry In Situ Hybridization Inherited Institutional Review Boards Intervention Label Laboratories Lead Leadership Malignant Neoplasms Malignant neoplasm of ureter Malignant neoplasm of urinary bladder Measures Memorial Sloan-Kettering Cancer Center Methodology Microdissection Modeling Molecular Morphology Mus Mutate Mutation Needle biopsy procedure Neoplasm Metastasis Nucleic Acids Paraffin Embedding Pathologic Pathology Patient-Focused Outcomes Patients Pelvic Cancer Phenotype Pilot Projects Plasma Play Preparation Process Proteomics Protocols documentation Public Health Quality Control RNA Radical Cystectomy Recording of previous events Recurrence Renal carcinoma Research Research Personnel Research Project Grants Resource Sharing Risk Role Sampling Scanning Serum Services Specimen Standardization T cell clonality Therapeutic Therapeutic Human Experimentation Tissue Embedding Tissue Microarray Tissue Procurements Tissue Sample Tissues Translational Research Transurethral Resection Tube United States Urethral Cancer Urine Urothelium Whole Blood Work Xenograft Model advanced disease anticancer research base cell free DNA clinical sequencing data quality design digital exome sequencing exosome follow-up genetic analysis human tissue immune checkpoint blockade improved laser capture microdissection molecular diagnostics mouse model neoplasm resource next generation sequencing novel novel marker patient privacy predictive marker prognostic programmed cell death ligand 1 prospective prospective test quality assurance relational database response response biomarker transcriptome sequencing tumor

项目摘要

PROJECT SUMMARY/ABSTRACT The Biospecimen Repository Core is designed to provide support to the basic translational research efforts of the SPORE in Bladder Cancer. The Core will play a central role in collecting, annotating, storing, distributing, and tracking urothelial cancer biospecimens (tissue, urine, and blood) from patients enrolled in biospecimen banking and therapeutic research protocols. Detailed biospecimen annotation, including documentation of pre- analytic processing variables, pathology findings, and patient clinical history information will be recorded in robust relational databases. We will conduct rigorous data quality assurance and quality control measures, and standardized longitudinal follow-up of all consented patients with materials in the urothelial cancer biospecimen repository. The Core will also provide SPORE investigators with expert histopathological evaluation of tumor samples both from patients enrolled on research protocols and from xenograft models. The Core will also provide assistance in performing and interpreting immunohistochemical and in situ hybridization assays, in selecting tissue for microdissection and construction of arrays. Given the significant morphologic heterogeneity of bladder cancers, these services require expertise beyond what MSK Pathology Core can provide, underscoring the importance of the role and input of the Core Directors. The specific aims of the core are: Specific Aim 1. To maintain and expand a model urothelial cancer resource designed to collect, annotate, store, process, and distribute biospecimens for translational urothelial cancer research. Specific Aim 2. To perform systematic pathologic evaluation of all human and animal biospecimens and preparation of appropriate biospecimens for use by SPORE investigators. Each of the research projects relies extensively on the Biospecimen Repository Core to achieve their translational research objectives. For RP-1, the core will aid with the prospective molecular characterization of urothelial cancers for mutations in DNA damage response genes and will assist with the preparation of tumor samples for whole-exome sequencing to identify novel biomarkers of cisplatin-sensitivity and with blood and urine samples for cell-free DNA analysis. For RP-2, the core will provide blood samples and matched tumor for next-generation sequencing analyses to identify genes, which when mutated are associated with increased inherited risk for urothelial cancer. For RP-3, the core will provide blood and tissue samples for multi-platform analyses (PD-L1 immunohistochemistry, T-cell clonality, tumor mutational load, whole exome sequencing (WES), RNAseq, TCRseq, immunoSEQ and MDSC quantitation) with the goal of identifying predictive biomarkers of response to immune checkpoint blockade. For RP-4, the Biospecimen Repository Core will assist in the characterization of xenograft models used to study novel strains of bacillus Calmette-Guérin (BCG) and with the analysis of samples from patients with urothelial cancer to identify predictive biomarkers of response to BCG immunotherapy.

项目概要/摘要生物样本存储库核心旨在为基础转化研究工作提供支持膀胱癌中的 SPORE 将在收集、注释、存储、分发、跟踪参与生物样本的患者的尿路上皮癌生物样本（组织、尿液和血液）银行和治疗研究协议。详细的生物样本注释，包括预记录。分析处理变量、病理结果和患者临床病史信息将记录在我们将执行严格的数据质量保证和质量控制措施，以及对所有同意使用尿路上皮癌生物样本中的材料的患者进行标准化纵向随访 Core 还将为 SPORE 研究人员提供肿瘤的专家组织病理学评估。 The Core 还将采集来自参与研究方案的患者和异种移植模型的样本。为执行和解释免疫组织化学和原位杂交测定提供帮助，鉴于显着的形态异质性，选择用于显微切割和构建阵列的组织。对于膀胱癌，这些服务需要的专业知识超出了 MSK 病理学核心所能提供的范围，强调核心董事的作用和投入的重要性核心的具体目标是：具体目标 1. 维护和扩展尿路上皮癌模型资源，旨在收集、注释、存储、处理和分发用于转化尿路上皮癌研究的生物样本。具体目标 2. 对所有人类和动物生物样本进行系统病理学评估准备适当的生物样本供 SPORE 研究人员使用。每个研究项目主要依靠生物样本存储库核心来实现其目标对于 RP-1 的转化研究目标，核心将有助于进行前瞻性分子表征。尿路上皮癌 DNA 损伤反应基因突变，并有助于肿瘤的形成用于全外显子组测序的样本，以识别顺铂敏感性的新生物标志物以及血液和对于 RP-2，核心将为进行无细胞 DNA 分析提供血液样本和匹配的肿瘤。下一代测序分析可识别基因，这些基因突变时与增加的基因相关对于 RP-3，核心将为多平台提供血液和组织样本。分析（PD-L1 免疫组织化学、T 细胞克隆性、肿瘤突变负荷、全外显子组测序 (WES)、RNAseq、TCRseq、immunoSEQ 和 MDSC 定量），目的是识别预测对于 RP-4，生物样本存储库核心将提供免疫检查点封锁反应的生物标志物。协助表征用于研究卡介苗新菌株的异种移植模型 (BCG) 并分析尿路上皮癌患者的样本，以确定以下疾病的预测生物标志物：对 BCG 免疫治疗的反应。